News

The proof-of-concept trial of the drug, PRS-211,375, will be conducted among healthy subjects experiencing pain following third molar dental extraction. The single-center, randomized, double-blinded, single-dose intravenous study will

Cyanokit is in development for the treatment of known or suspected cyanide poisoning and is currently marketed in France by another Merck KGaA affiliate, Merck Sante. The FDA

Praecis will work with the FDA to discontinue the limited distribution of the product in the United States as soon as possible and will no longer pursue commercialization

The compound, AEOL 11207, has shown potential in preclinical testing as a once-every-other-day oral therapeutic treatment option for a number of CNS disorders, most likely Parkinson's disease. However,

Lipodystrophy is a condition dominated by fat redistribution, particularly visceral fat accumulation and subcutaneous fat loss. No drugs are currently approved for the treatment of HIV lipodystrophy. According

The company expects to enroll approximately 60 to 70 patients with treatment-naive, unresectable pancreatic adenocarcinoma in this single-arm, open-label trial, which will be conducted at multiple investigator sites

Mesothelioma is a type of cancer arising from the cells, known as mesothelium, with the majority of cancers beginning in the chest cavity. The incidence of mesothelioma increases

The biopharmaceutical company will now apply for wider European approval through the mutual recognition procedure (MRP). In the treatment of sexual deviations in men, administration of a drug

If the endpoints in the study are met, ZymoGenetics plans to submit a biologics licensing application (BLA) for rhThrombin to the FDA in late 2006. The 400 patient